KR20170057020A - Cosmetic composition with the extract of Cornus officinalis for the improvement of skin redness or face redness - Google Patents
Cosmetic composition with the extract of Cornus officinalis for the improvement of skin redness or face redness Download PDFInfo
- Publication number
- KR20170057020A KR20170057020A KR1020150160611A KR20150160611A KR20170057020A KR 20170057020 A KR20170057020 A KR 20170057020A KR 1020150160611 A KR1020150160611 A KR 1020150160611A KR 20150160611 A KR20150160611 A KR 20150160611A KR 20170057020 A KR20170057020 A KR 20170057020A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- vegf
- skin
- flushing
- cosmetic composition
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
The present invention relates to a cosmetic composition for improving skin flushing or facial flushing containing corn oil or an extract thereof, and exhibits an excellent effect for improving skin flushing or facial flushing.
Description
The present invention relates to a cosmetic composition for improving skin flushing or facial flushing containing corn oil or its extract.
Skin redness, also called skin redness or facial redness, is known as a type of menopausal syndrome, but it also refers to the symptoms of reddening the skin by sensitizing itself to sunlight, heat, and stress.
Skin flushing (or facial flushing) is the most severe symptom in early winter when temperature changes are severe and dry. In recent years, not only women in their 10s to 20s but also men's skin flushes are increasing. Skin troubles due to seasonal changes are not a big concern, but if left untreated, they can develop into serious skin conditions such as rosacea and telangiectasis.
Skin redness is reported to be caused by angiogenic factors. Vascular endothelial growth factor (VEGF) is a typical angiogenic factor that induces angiogenesis. It is an important factor that regulates angiogenesis as well as vasculogenesis in vasodilation and embryogenesis.
On the other hand, the expression of VEGF is known to be enhanced by external stimuli such as ultraviolet rays. Secreted VEGF binds to VEGF receptors present on the surface of vascular endothelial cells and promotes vascular endothelial cell proliferation and secretion of extracellular matrix degrading enzymes, and is involved in mechanisms involved in vascular endothelial cell migration and adhesion of vascular endothelial cells .
Angiogenesis is the process by which new blood vessels are created from existing blood vessels. It involves the migration of vascular endothelial cells that constitute blood vessels, the infiltration reaction through the extracellular matrix (ECM) which is an intercellular barrier, the growth of blood vessels and the formation of blood vessels (Tube-like formation) do.
In normal conditions, the equilibrium between the angiogenesis inhibitors and the angiogenesis inhibitors is maintained, and when the equilibrium is broken, the angiogenesis occurs. In addition to skin flushing and facial flushing, new blood vessel formation is known to affect skin aging, wound healing, stain, dark circles, and hair.
On the other hand, if the skin barrier function is impaired by external stimuli, excessive inflammation and immune reaction will occur, and secretion of various cytokines, chemokines, growth factors including VEGF in damaged tissues and cells . Through this, a variety of immune cells collect through the blood vessels and lymphatic vessels into the tissues, resulting in an inflammatory reaction.
Increased angiogenesis and vascular permeability caused by secreted VEGF promotes the process of aggregation of various immune cells into damaged tissues through the blood vessels, which, if persistent, leads to chronic inflammation. Through this mechanism, the skin appears red, and when it is severe, microvascularity appears on the surface of the skin.
In the present invention, a material derived from natural materials capable of improving facial flushing or skin flushing is discovered and developed as a cosmetic composition.
The present invention provides a cosmetic composition for improving skin flushing or facial flushing, which comprises corn oil or an extract thereof as an active ingredient.
Cornus officinalis ) is a deciduous broad-leaved arboreous arborea belonging to the family Cornaceae, which is the dried flesh of corn oil. The property is slightly warm, tasteless and poisonous. It is an elliptical nucleus and it is green at first, but it ripens red from August to October. Fruit (fruit) contains glycosides such as cornin, morroniside, loganin, tannin and saponin, and organic acids such as wine, malic and tartaric acid. have.
Corn oil is harvested after the upper part of mid-October, and the flesh and seed are separated, and the flesh quality is used as the material of wine, tea and Chinese medicine. According to the "Dongbibogam" and the "Fragrant Bulgari", it is said that it has effects such as strengthening of 阴 阴, 肾 精 and 肾气, and convergence. In addition, the effect of removing harmful oxygen is also excellent, so that it has the effect of softening the skin. Headache, tinnitus, blood circulation, fever, and menstrual hyperactivity. The diet is also used for folk remedies such as sweat and enuresis.
On the other hand, in the cosmetic composition for skin flushing or facial flushing improvement of the present invention, it is preferable to use an extract obtained by adding ethanol as a solvent to the acidified milk oil. At this time, the ethanol is more preferably 70% ethanol.
In the cosmetic composition for improving skin flushing or facial flushing, the skin flushing or facial flushing improvement may preferably be through inhibition of vascular endothelial growth factor (VEGF) expression.
The cosmetic composition containing the crude oil or extract thereof of the present invention exerts an excellent effect for improving skin flushing or facial flushing.
Fig. 1 shows the results of the cytotoxicity evaluation of the extract of corn oil.
Fig. 2 shows that the treatment with Cornouin extract inhibited the secretion of VEGF.
FIG. 3 shows that treatment with the Cornouin extract decreases the amount of NO produced which is increased by VEGF treatment.
Figure 4 shows that treatment of the Cornus extract reduces the activity of eNOS induced by VEGF treatment.
FIG. 5 shows that treatment with the Cornouin extract inhibited the growth of endothelial cells induced by treatment with VEGF.
Fig. 6 shows that the treatment of Cornouin Extract inhibits angiogenesis induced by treatment of VEGF.
When the skin is exposed to various stimulants including UV, the expression of VEGF is increased, and the increased VEGF plays an important role in neovascularization and vasodilation. However, according to the present invention, it was confirmed that the VEGF expression was reduced by the treatment with the corn oil extract, and the angiogenesis was inhibited in the group treated with the corn oil extract.
On the other hand, VEGF increased by UV and the like increases NO production rate through activation of eNOS (endothelial NOS), and regulates these factors, thereby participating in neovascularization and vasodilation. However, it was confirmed that the amount of NO produced increased by VEGF when the extract of corn oil was treated. In addition, it was confirmed whether or not the extract of corn oil affects the activity of eNOS, and it was confirmed that the treatment with corn oil extract decreased the activity of eNOS induced by VEGF treatment.
On the other hand, VEGF has been reported to promote the growth and migration of endothelial cells in addition to neovascularization and vasodilation. In the present invention, the inhibition of endothelial cell growth by the extract of corn oil was confirmed, and it was confirmed that the growth of endothelial cells was inhibited in the group treated with the corn oil extract.
Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the scope of the present invention is not limited to the following embodiments, and includes modifications of equivalent technical ideas.
[Example 1: Preparation of acidified milk extract]
500 g of 70% ethanol as a solvent was added to 25 g of the mixed powder prepared by pulverizing dried corn syrup, and the mixture was stirred and extracted at 500 rpm for 3 hours using a stirrer (Heidoph, standard: MR3001, MR3001K). After extraction, the extract solution was filtered with a filter paper, and the resulting filtrate was concentrated under reduced pressure at 45 ° C using a concentrator (Heidolph, LABOROTA 4000) to obtain a mixed extract. In the following experiment, the extract obtained through the above procedure was used as a sample.
[Experimental Example 1: Evaluation of cytotoxicity]
In this experimental example, the cytotoxicity evaluation of the crude oil extract was evaluated by MTT assay.
Human fibroblasts (HDF) and endothelial cells (HUVEC) were cultured in each well of a 96-well plate at a concentration of 1 × 10 5 cells / ml, and then the extract of corn oil prepared in Example 1 was applied to the 96-well plate 100 [mu] L of each solution was added to each well at a concentration of 25, 50, 100, and 200 [mu] g / mL, followed by culturing for 24 hours.
After 24 hours, 20 쨉 l of MTT solution diluted with PBS at a concentration of 5 mg / ml was added to each well, and the mixture was incubated for 2 hours. An ELISA reader (VICTOR3, Perkin Elmer) was eluted with 100 쨉 l of isopropanol Absorbance at 570 nm.
The absorbance of the experimental group (sample treated group) and the control group (untreated group) was measured and converted into cytotoxicity evaluation results, and the results are shown in FIG. Here, the cell viability (%) was obtained by the following formula (1).
As a result of the experiment, it was confirmed that the extract of corn oil was not cytotoxic in the test concentration range as shown in Fig. 1 (Fig. 1). Fig. 1 shows the results of the cytotoxicity evaluation of the extract of corn oil.
[ Experimental Example 2: Acid Yield Extract Angiogenic factor ( VEGF ) Expression Control ability Confirm]
When the skin is exposed to various stimulus sources including UV, the expression of VEGF is increased, and thus the expressed VEGF plays an important role in the neovascularization process. Therefore, in this Experimental Example, the expression of VEGF by ultraviolet (UV) and the control of VEGF expression by the treatment with Sanskrit oil extract were examined by ELISA method.
Was inoculated so that the 5 × 10 5 cell / well of HDF cells in 6-well plates, and cultured for 24 hours. After the incubation, the culture medium was discarded, and a serum-free medium was added thereto, followed by starvation for 24 hours.
After 24 hours, the cells were washed with DPBS and in the presence of DPBS UVB (12.5 mJ / cm 2 ). After the UVB stimulation, the sample (Example 1) was diluted at a concentration of 100 μl / ml in a medium containing no serum and treated with 2 ml each plate. After the treatment, VEGF secreted in culture medium was measured by ELISA method (Human VEGF ELISA assay, R & D system, DVE00) using a cell culture supplemented with culture for 24 hours.
As shown in FIG. 2, it was confirmed that the secretion of VEGF was suppressed at a concentration of 100 μl / ml of the crude oil extract. Fig. 2 shows that treatment with the extract of corn oil suppresses the secretion of VEGF.
[ Experimental Example 3: NO production of extract from corn oil Low performance evaluation]
Increased VEGF promotes the production of NO through activation of endothelial NOS (eNOS), and regulates these factors to play a role in neovascularization and vasodilation.
HUVEC was inoculated on a 24-well plate at 8 × 10 5 cells / well and cultured for 24 hours. After the incubation, a starvation process was performed for 24 hours using a medium containing 1% of serum.
After 24 hours, the sample (Example 1) was diluted to a concentration of 100 쨉 l / ml in the medium containing 1% of serum, and treated with 500 쨉 l each plate. After 1 hour, VEGF was treated to a final concentration of 10 ng / ml. After the treatment, the cells were further cultured for 24 hours, and the degree of production of NO produced in the culture solution was measured by ELISA method (Griess reagent system, Promega, G2930) using the cultured cell culture.
As shown in FIG. 3, the extract of corn oil decreased the amount of NO produced by VEGF treatment. FIG. 3 shows that treatment with the Cornouin extract decreases the amount of NO produced which is increased by VEGF treatment.
[ Experimental Example 4: Extract of corn oil eNOS activation Inhibition evaluation]
Whether or not the sample with NO production inhibiting ability (Example 1) affects the activity of eNOS was confirmed by Western blotting.
HUVEC was inoculated on a 6-well plate at 5 × 10 5 cells / well and cultured for 24 hours. After the incubation, starvation was carried out for 24 hours using a medium containing 1% of serum.
After 24 hours, the sample (Example 1) was diluted at a concentration of 100 쨉 l / ml in a medium containing 1% of serum and treated with 500 쨉 l of each plate. After 1 hour, VEGF was treated to a final concentration of 10 ng / ml. After the treatment, the amount of COX-2 protein expressed from the cells cultured for additional 24 hours was examined.
The HUVEC cultured in the above was washed with DPBS, treated with 100 μl of lysis buffer, and then recovered using a scraper. The recovered cells were incubated in ice for 1 hour and centrifuged at 12,000 x g for 20 minutes at 4 ° C.
The supernatant was transferred to a new tube, and the protein was quantitated using the BCA method. Protein, PBS and 5x sample buffer were then mixed to a total volume of 25 [mu] l and denatured by keeping in boiling water for 5 minutes.
The sample prepared above was loaded on SDS gel and electrophoresed at 100V. After electrophoresis, transfer was carried out to transfer the proteins in the gel to the membrane. Then, the primary antibody was reacted at 4 ° C for 16 hours on the membrane, followed by washing with TBS-T twice for 5 minutes. Subsequently, the secondary antibody was reacted at room temperature for 1 hour, and then washed with TBS-T 4 times for 10 minutes. Thereafter, the membrane was subjected to ECL (Enhanced Chemiluminescence) reaction, and the membrane was inserted into a cassette and detected using a film. At this time, actin antibody was reacted in the same manner as above to confirm the band.
As a result of the experiment, it was confirmed that the activity of eNOS induced by VEGF treatment in the group treated with the extract of corn oil was remarkably decreased as shown in Fig. Figure 4 shows that treatment of the Cornus extract reduces the activity of eNOS induced by VEGF treatment.
[ Experimental Example 5: Growth of Endothelial Cells from Corn oil Extract Inhibition Confirm]
VEGF promotes the growth and migration of endothelial cells and is involved in the mechanism of neovascularization and vasodilation. In this experiment, the endothelial cell growth was measured in order to confirm the endothelial cell growth inhibitory ability of the extract of corn oil.
HUVEC was inoculated on a 6-well plate at 1 × 10 5 cells / well and cultured for 24 hours. After the incubation, starvation was carried out for 24 hours using a medium containing 1% of serum.
After 24 hours, the sample (Example 1) was diluted at a concentration of 100 쨉 l / ml in a medium containing 1% of serum and treated with 500 쨉 l of each plate. After 1 hour, VEGF was treated to a final concentration of 10 ng / ml. After 24 hours incubation, the cells were removed and the number of cells was counted using a typan blue and a hemocytometer.
As shown in FIG. 5, it was confirmed that the growth of endothelial cells was inhibited in the group treated with the corn oil extract. FIG. 5 shows that treatment with the Cornouin extract inhibited the growth of endothelial cells induced by treatment with VEGF.
[ Experimental Example 6: Creation of neovascularization of the extract of corn oil Inhibition Confirm]
Was inoculated so that the 5 × 10 5 cell / well of HDF cells in 24-well plates that cover the underlying sleep (cover slip), and cultured for 3 days. Three days later, HUVEC was inoculated in wells inoculated with HDF cells at a concentration of 6 × 10 3 cells / well. At this time, EBM-2 containing 10% serum was used as a medium.
After 24 hours, the sample (Example 1) was diluted to a concentration of 100 쨉 l / ml and placed in the remaining wells except for the control group, and the pretreatment was carried out for 1 hour. One hour later, VEGF was treated to a final concentration of 10 ng / ml, and suramin (20 μM) was treated as a negative control. Once or twice a day, VEGF and suramin were replaced with or without a sample. After incubation for about 10 days, the ability to inhibit angiogenesis was confirmed by fluorescent staining.
As a result of the experiment, it was confirmed that the angiogenesis was inhibited in the group treated with the corn oil extract, as shown in FIG. Fig. 6 shows that the treatment of Cornouin Extract inhibits angiogenesis induced by treatment of VEGF.
Claims (4)
In addition,
A cosmetic composition for improving skin flushing or facial flushing characterized by being extracted with ethanol as a solvent.
The above-
70% < / RTI > ethanol.
The skin flushing or facial flushing improvement can be achieved by,
(VEGF) expression in the skin of a subject. The cosmetic composition according to claim 1, wherein the cosmetic composition is a cosmetic composition for improving skin flushing or facial flushing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150160611A KR101829209B1 (en) | 2015-11-16 | 2015-11-16 | Cosmetic composition with the extract of Cornus officinalis for the improvement of skin redness or face redness |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150160611A KR101829209B1 (en) | 2015-11-16 | 2015-11-16 | Cosmetic composition with the extract of Cornus officinalis for the improvement of skin redness or face redness |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20170057020A true KR20170057020A (en) | 2017-05-24 |
| KR101829209B1 KR101829209B1 (en) | 2018-02-14 |
Family
ID=59051446
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150160611A KR101829209B1 (en) | 2015-11-16 | 2015-11-16 | Cosmetic composition with the extract of Cornus officinalis for the improvement of skin redness or face redness |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101829209B1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019231134A1 (en) | 2018-05-31 | 2019-12-05 | 주식회사 엑소코바이오 | Composition for alleviating facial redness, comprising stem cell-derived exosomes as active ingredient |
| KR102649069B1 (en) | 2018-05-31 | 2024-03-19 | 주식회사 엑소코바이오 | Composition for improving face redness comprising an exosome derived from stem cell as an active ingredient |
| KR102122980B1 (en) | 2018-12-28 | 2020-06-18 | 한국프라임제약주식회사 | Composition for relieving facial flushing associated with menopausal phase containing medicinal perilla leaf extract as an active ingredient |
-
2015
- 2015-11-16 KR KR1020150160611A patent/KR101829209B1/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| KR101829209B1 (en) | 2018-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Myricetin attenuated LPS induced cardiac injury in vivo and in vitro | |
| Brâkenhielm et al. | Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes | |
| Kim et al. | Cinnamon subcritical water extract attenuates intestinal inflammation and enhances intestinal tight junction in a Caco-2 and RAW264. 7 co-culture model | |
| JP6554181B2 (en) | Herbal extract, method for producing and using the same | |
| TWI444194B (en) | Anti-cancer extract and compounds | |
| KR101829209B1 (en) | Cosmetic composition with the extract of Cornus officinalis for the improvement of skin redness or face redness | |
| KR20170045074A (en) | The Productive Method of Fremenatation Beverage and cosmetic ingredients with Gynura Procumbens | |
| Zhu et al. | Liraglutide, a TFEB‐mediated autophagy agonist, promotes the viability of random‐pattern skin flaps | |
| KR101771695B1 (en) | Pharmaceutical composition for the prevention and treatment of obesity comprising Spirulina maxima as an active ingredient | |
| Ly et al. | Vaccinium angustifolium (lowbush blueberry) leaf extract increases extravillous trophoblast cell migration and invasion in vitro | |
| KR101498665B1 (en) | Pharmaceutical composition and functional food for prevention or treatment of diabetic complications or angioedema comprising natural extract | |
| CN111356468A (en) | Composition for preventing or treating fibrotic disease comprising extract of Rhus toxicodendron | |
| CN102631358A (en) | Application of polydatin in preparing medicament for treating diabetic nephropathy | |
| KR20150077794A (en) | Anti-obesity composition comprising herbal extracts as an active ingredient | |
| KR20150085991A (en) | Skin whitening compositions containing oriental medicine natural herb | |
| CN110201025B (en) | Application of cyclocarya paliurus extract in preparation of medicine for treating or preventing diabetic cardiomyopathy | |
| Wen et al. | Alleviating Effect of Mulberry Leaf 1-Deoxynojirimycin on Resistin-Induced Hepatic Steatosis and Insulin Resistance in Mice | |
| Song et al. | Atractylenolide II ameliorates myocardial fibrosis and oxidative stress in spontaneous hypertension rats | |
| Li et al. | The protective effect of Bajijiasu on the treatment of hypertensive nephropathy in rats | |
| CN114832025B (en) | Preparation method and application of ginseng adventitious root crude extract | |
| TWI653046B (en) | Herbal compound extract for improving diabetes with liver damage and liver fibrosis and use thereof | |
| KR20210087999A (en) | Pharmaceutical composition for preventing or treating atopic dermatitis comprising clonal stem cells | |
| KR20210072543A (en) | Healthful composition comprising a jujube flesh extract | |
| CN116036153B (en) | Use of hops extract in the preparation of a product for the treatment or prevention of depression, complications of depression, anxiety | |
| KR102432990B1 (en) | Composition for the prevention of skin cancer of inhibition of skin cancer metastasis containing citrus unshiu peel extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |